US 11,684,669 B2
CpG-adjuvanted SARS-CoV-2 virus vaccine
Andreas Meinke, Pressbaum (AT); Michael Möhlen, Vienna (AT); Christoph Reinisch, Siegenfeld (AT); Robert Schlegl, Siegenfeld (AT); Christian Taucher, Vienna (AT); John Campbell, Emeryville, CA (US); David Novack, Emeryville, CA (US); Robert S. Janssen, Emeryville, CA (US); and Jürgen Heindl-Wruss, Vienna (AT)
Assigned to Valneva Austria GmbH, Vienna (AT); and Dynavax Technologies Corporation, Emeryville, CA (US)
Filed by Valneva Austria GmbH, Vienna (AT); and Dynavax Technologies Corporation, Emeryville, CA (US)
Filed on Sep. 10, 2021, as Appl. No. 17/471,904.
Application 17/471,904 is a continuation of application No. PCT/IB2021/052858, filed on Apr. 6, 2021.
Application PCT/IB2021/052858 is a continuation of application No. PCT/US2021/020313, filed on Mar. 1, 2021.
Claims priority of provisional application 62/983,737, filed on Mar. 1, 2020.
Claims priority of application No. 20168324 (EP), filed on Apr. 6, 2020; application No. 20202124 (EP), filed on Oct. 15, 2020; application No. 20211936 (EP), filed on Dec. 4, 2020; application No. 21154645 (EP), filed on Feb. 1, 2021; and application No. 21160933 (EA), filed on Mar. 5, 2021.
Prior Publication US 2023/0038284 A1, Feb. 9, 2023
Int. Cl. C12N 7/00 (2006.01); A61K 39/215 (2006.01); A61K 39/00 (2006.01)
CPC A61K 39/215 (2013.01) [A61K 2039/545 (2013.01); A61K 2039/55561 (2013.01)] 30 Claims
OG exemplary drawing
 
1. A severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) immunogenic composition comprising i) an inactivated SARS-CoV-2 whole virus particle comprising an S protein having at least 96% amino acid sequence identity to SEQ ID NO: 3; ii) a CpG-containing oligodeoxynucleotide (CpG-ODN) consisting of the sequence of SEQ ID NO: 4; and iii) an alum adjuvant;
wherein the immunogenic composition induces neutralizing antibodies against SARS-CoV-2 in a subject immunized intramuscularly with the immunogenic composition; and
wherein the immunogenic composition does not induce antibody-dependent enhancement of SARS-CoV-2-associated disease in the subject.